✦ LIBER ✦

Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)

✍ Scribed by Melamed, Isaac Reuven; Wasserman, Richard L.; Stein, Mark; Rubinstein, Arye; Puck, Jennifer M.; Gupta, Sudhir; Engl, Werner; Leibl, Heinz; Yel, Leman; Schiff, Richard I.

Book ID: 123250290
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 41 KB
Volume: 133
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2013.12.645

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Pharmacokinetics of Facilitat

Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)

✍ Melamed, I.; Wasserman, R.L.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Tolerability and Efficacy of Facilitated

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

✍ Wasserman, R.L.; Melamed, I.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 41 KB